aTyr Pharma, Inc. (ATYR)

aTyr Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.59	0.35	10.39	0	10.46	0.42
Revenue Growth (YoY)	-94.34%	-96.60%	-	-	2377.49%	-
Gross Profit	0.59	0.35	10.39	0	10.46	0.42
Selling, General & Admin	13.08	12.98	13.98	10.75	9.08	9.35
Research & Development	46.28	42.29	42.81	23.26	17.29	14.05
Operating Expenses	59.36	55.27	56.79	34.02	26.37	23.4
Operating Income	-58.77	-54.92	-46.4	-34.02	-15.91	-22.98
Other Expense / Income	-4.84	-4.53	-1.07	-0.25	0.31	0.63
Pretax Income	-53.93	-50.39	-45.34	-33.77	-16.22	-23.6
Net Income	-53.93	-50.39	-45.34	-33.77	-16.22	-23.6
Shares Outstanding (Basic)	66	54	28	19	9	3
Shares Outstanding (Diluted)	66	54	28	19	9	3
Shares Change	57.72%	88.63%	48.94%	108.30%	172.98%	56.66%
EPS (Basic)	-0.90	-0.94	-1.60	-1.77	-1.77	-7.03
EPS (Diluted)	-0.90	-0.94	-1.60	-1.77	-1.77	-7.03
Free Cash Flow	-57.98	-37.42	-43.35	-33.22	-15.49	-20.04
Free Cash Flow Per Share	-0.88	-0.70	-1.52	-1.74	-1.69	-5.97
Gross Margin	100.00%	100.00%	100.00%	-	100.00%	100.00%
Operating Margin	-9994.56%	-15557.79%	-446.79%	-	-152.19%	-5445.02%
Profit Margin	-9171.60%	-14274.50%	-436.53%	-	-155.18%	-5593.13%
Free Cash Flow Margin	-9860.88%	-10600.85%	-417.37%	-	-148.11%	-4749.05%
EBITDA	-51.17	-47.65	-43.64	-32.46	-14.96	-22.24
EBITDA Margin	-8702.89%	-13498.02%	-420.21%	-	-143.07%	-5269.43%
Depreciation & Amortization	2.76	2.74	1.7	1.3	1.27	1.37
EBIT	-53.93	-50.39	-45.34	-33.77	-16.22	-23.6
EBIT Margin	-9171.60%	-14274.50%	-436.53%	-	-155.18%	-5593.13%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).